RegulatoryCompany release

FDA sets 31 March 2027 action date for Atara's resubmitted tab-cel BLA

🇺🇸 Atara Biotherapeutics, Inc. (ATRA) · Tue 10 Nov 2026

Atara Biotherapeutics says the FDA accepted its resubmitted application for tabelecleucel in EBV+ PTLD, while cash of $9.9 million is expected to last into mid-2027.

Atara Biotherapeutics has announced that the US Food and Drug Administration has accepted its resubmitted biologics licence application (BLA) for tabelecleucel (tab-cel), a therapy for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). The company disclosed the news alongside its third-quarter 2026 results.

The agency has classed the resubmission as Class 2 and set a Prescription Drug User Fee Act (PDUFA) target action date of 31 March 2027. As general context, a Class 2 resubmission is the longer of the two review categories for applications returned after a complete response letter, with a six-month review goal.

Approval would trigger a $31 million milestone payment from Atara's partner, Pierre Fabre, according to the company.

On finances, Atara reported cash of $9.9 million as of 30 September 2026. It expects this to fund operations into mid-2027, a horizon that falls only a few months after the FDA's target action date.

What it means for your team

  • Regulatory teams tracking cell therapies for rare post-transplant conditions should note 31 March 2027 as the FDA decision target for tab-cel.
  • Market-access and partnering teams should note that a $31 million milestone from Pierre Fabre is tied to approval, so the FDA outcome carries commercial weight for both companies.
  • Atara's stated cash runway into mid-2027 leaves a narrow margin after the action date, which is relevant to anyone assessing supply or programme continuity.

Company's press release (SEC filing): Atara Biotherapeutics, Inc. ↗

Article written by VigiEye from the official source (Atara Biotherapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →